The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
نویسندگان
چکیده
منابع مشابه
the assessment of response to adjuvant chemotherapy with cmf in triple negative breast cancer.
introduction: breast cancers are divided into at least 4 sub types on the basis of gene expression profiles and expression of receptors as measured by ihc (immunohistochemical). triple negative breast cancer (tnbc) is more chemosensitive yet, it is much harder to detect than other sub types. at present lack of highly effective therapeutic targets for tnbc, leaves standard chemotherapy, as the o...
متن کاملTriple-Negative Breast Cancer: Adjuvant Therapeutic Options
Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a more aggressive clinical course with increased risk of disease progression and poorer overall survi...
متن کاملThe Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
INTRODUCTION Breast cancers are divided into at least 4 sub Types on the Basis of gene expression profiles and expression of receptors as measured by IHC (Immunohistochemical). Triple negative breast cancer (TNBC) is more chemosensitive yet. It is much harder to detect than other sub types. At present lack of highly effective therapeutic targets for TNBC, standard chemotherapy is the only medic...
متن کاملMetronomic chemotherapy for triple negative breast cancer?
Despite the incidence for women older than 70 years being 33%, they are usually excluded from screening schedules and clinical trials. Furthermore, about 15% of breast cancers in older patients are of the triple-negative subtype (TNBC), which is known to be an aggressive histological subtype with very limited treatment options available, and associated with a very poor prognosis [1]. Indeed, th...
متن کاملPrediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
BACKGROUND Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based biomarkers that predict the response to standard adjuvant chemotherapy, so that patients a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2020
ISSN: 2234-943X
DOI: 10.3389/fonc.2020.01753